Abstract
Adrenergic receptor signaling and heart failure are inextricably linked. Beta-adrenergic receptors (β-ARs) serve not only as physiological modulators of heart rate and contractility, they are also primary therapeutic targets of individuals with heart failure as well as many other cardiovascular disorders. In light of these relationships, this short review will focus on the basic pharmacology distinguishing adrenergic receptor subtypes; on receptor subtype selective signaling; the molecular basis of β-AR gene expression; and, delve briefly into genetic variation of β-ARs that represents a potential basis of differential natural history of heart failure progression and that may serve as an underlying basis for therapeutic response.
Keywords: Adrenergic receptors, signaling, gene regulation, genetic variation, heart failure
Current Signal Transduction Therapy
Title:Beta-adrenergic Signaling: Complexities and Therapeutic Relevance to Heart Failure
Volume: 7 Issue: 2
Author(s): J. David Port
Affiliation:
Keywords: Adrenergic receptors, signaling, gene regulation, genetic variation, heart failure
Abstract: Adrenergic receptor signaling and heart failure are inextricably linked. Beta-adrenergic receptors (β-ARs) serve not only as physiological modulators of heart rate and contractility, they are also primary therapeutic targets of individuals with heart failure as well as many other cardiovascular disorders. In light of these relationships, this short review will focus on the basic pharmacology distinguishing adrenergic receptor subtypes; on receptor subtype selective signaling; the molecular basis of β-AR gene expression; and, delve briefly into genetic variation of β-ARs that represents a potential basis of differential natural history of heart failure progression and that may serve as an underlying basis for therapeutic response.
Export Options
About this article
Cite this article as:
David Port J., Beta-adrenergic Signaling: Complexities and Therapeutic Relevance to Heart Failure, Current Signal Transduction Therapy 2012; 7 (2) . https://dx.doi.org/10.2174/157436212800376645
DOI https://dx.doi.org/10.2174/157436212800376645 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interconnection of Estrogen/Testosterone Metabolism and Mevalonate Pathway in Breast and Prostate Cancers
Current Molecular Pharmacology EBI2, GPR18, and GPR17 – Three Structurally Related but Biologically Distinct 7TM Receptors
Current Topics in Medicinal Chemistry Relationships of Beta2- and Beta3--Adrenoceptor Polymorphisms with Obesity, Hypertension and Metabolic Syndrome
Current Hypertension Reviews A Validated UPLC Method Used for the Determination of Trandolapril and its Degradation Products as per ICH Guidelines
Current Pharmaceutical Analysis Medications not Intended for Treatment of Dyslipidemias and with a Variable Effect on Lipids
Current Pharmaceutical Design Can We Move Forward After ADVANCE?
Vascular Disease Prevention (Discontinued) Allograft-Induced Proliferation of Vascular Smooth Muscle Cells: Potential Targets for Treating Transplant Vasculopathy
Current Vascular Pharmacology Interstitial Lung Disease in Systemic Sclerosis: Pathophysiology, Current and New Advances in Therapy
Inflammation & Allergy - Drug Targets (Discontinued) A Scientific Approach to Anti-Ageing Therapies: State of the Art
Current Pharmaceutical Design Risk of Bleeding Related to Antithrombotic Treatment in Cardiovascular Disease
Current Pharmaceutical Design Patent Selections:
Recent Patents on Cardiovascular Drug Discovery SIRT1, a Calorie Restriction Mimetic, in a New Therapeutic Approach for Type 2 Diabetes Mellitus and Diabetic Vascular Complications
Endocrine, Metabolic & Immune Disorders - Drug Targets Anaemia, Polycythaemia and Chronic Heart Failure
Current Cardiology Reviews Current Status of Computer-Aided Drug Design for Type 2 Diabetes
Current Computer-Aided Drug Design Protective Effects of TRPV1 Activation Against Cardiac Ischemia/ Reperfusion Injury is Blunted by Diet-Induced Obesity
Cardiovascular & Hematological Disorders-Drug Targets Regulation and Quantification of Cellular Mitochondrial Morphology and Content
Current Pharmaceutical Design Nano-constructed Carriers Loaded With Antioxidant: Boon For Cardiovascular System
Current Pharmaceutical Design Physical Activity and Diabetic Cardiomyopathy: Myocardial Adaptation Depending on Exercise Load
Current Diabetes Reviews Understanding Respiratory Syncytial Virus Infection to Improve Treatment and Immunity
Current Molecular Medicine Mepolizumab and Eosinophil-Mediated Disease
Current Medicinal Chemistry